Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01100684 · ClinicalTrials.gov registry record · Phase 3
Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)
A Phase 3 study, sponsored by Tioga Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 611
- Enrollment target
NCT01100684 is a Phase 3 study that has completed, run by Tioga Pharmaceuticals. The registered enrollment target is 611 participants.
The verdict
NCT01100684, a Phase 3 study, has completed, sponsored by Tioga Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 611 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether asimadoline is safe and effective at treating D-IBS.
Interventions
- DRUG Placebo
- DRUG Asimadoline
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 611 participants |
| Start Date | 2010-05 |
| Est. Completion | 2013-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01100684
The ClinicalTrials.gov registry entry for NCT01100684 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 611 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Tioga Pharmaceuticals, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01100684 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01100684 about?
NCT01100684 is a clinical study titled "Study of Asimadoline to Treat Diarrhea-Predominant Irritable Bowel Syndrome (D-IBS)". The purpose of this study is to determine whether asimadoline is safe and effective at treating D-IBS.
What is the current status of trial NCT01100684?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 611 participants. The study started on 2010-05. Estimated completion is 2013-06.
What interventions are being tested in trial NCT01100684?
The interventions under investigation include: Placebo (DRUG), Asimadoline (DRUG).
Who is sponsoring clinical trial NCT01100684?
This trial is sponsored by Tioga Pharmaceuticals, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.